Beta cell glucose sensitivity identifies clinical response to disease-modifying therapies initiated at stage 3 type 1 diabetes onset.

Diabetologia
2026
https://researcherprofiles.org/profile/774761459
41817687
Evans-Molina C, Gitelman SE, Mari A, Ferrannini E